Coastal Biotech
Zanzibar-based marine biotech startup using seaweed to make biostimulants, crop protectants, and bio-based materials.
PUBLIC
| Name | Coastal Biotech |
| Tagline | Zanzibar-based marine biotech startup using seaweed to make biostimulants, crop protectants, and bio-based materials. |
| Headquarters | Zanzibar, Tanzania |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Agtech |
| Technology | Biotech / Life Sciences |
| Geography | Sub-Saharan Africa |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Pre-seed |
Links
PUBLIC
- Website: https://coastalbiotech.co.tz/
- LinkedIn: https://www.linkedin.com/company/coastal-biotech-ltd
Executive Summary
PUBLIC
Coastal Biotech is an early-stage marine biotech company building an integrated manufacturing operation for seaweed-derived agricultural inputs, a bet that leverages a local resource in Zanzibar to address global demand for sustainable crop solutions [Perplexity Sonar Pro Brief, retrieved 2026]. The company's focus on converting macroalgae into organic biostimulants and crop protectants positions it at the intersection of climate-resilient agriculture and the bioeconomy, a sector attracting increasing investor interest for its potential to decarbonize food systems.
Founded by Lavine Irvine, who brings a data science and operational efficiency background from roles at GSK and S&P Global Ratings, the venture is structured as a fully integrated manufacturer, a model that includes R&D, formulation design, and contract manufacturing [NextCapital, retrieved 2026] [Perplexity Sonar Pro Brief, retrieved 2026]. This end-to-end approach is ambitious for a pre-seed African startup and suggests a strategy to capture more value from the seaweed supply chain rather than just selling raw extracts.
Public traction is currently demonstrated through accelerator participation and hiring intent, not disclosed commercial contracts. The company was part of the 2025 SAIS Accelerator cohort and is actively recruiting for a specialized Seaweed Biotechnologist role, signaling a commitment to deep technical development [SAIS Accelerator, retrieved 2026] [Perplexity Sonar Pro Brief, retrieved 2026]. No priced equity funding rounds have been publicly reported, indicating the company is likely in a grant-funded or bootstrapped phase as it works to validate its integrated model.
Over the next 12-18 months, the key milestones to watch are the progression of its planned seaweed fertilizer factory, the signing of initial offtake agreements with agricultural or biomanufacturing clients, and the closing of an institutional seed round to fund scaled production.
Data Accuracy: YELLOW -- Core product claims and accelerator participation are confirmed; founder background is partially corroborated; funding and customer details are not publicly available.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Agtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Sub-Saharan Africa |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Pre-seed |
Company Overview
PUBLIC
Coastal Biotech Ltd. is a marine biotechnology company headquartered in Zanzibar, Tanzania, focused on converting locally sourced seaweed into agricultural and industrial products. The company's founding narrative centers on leveraging Zanzibar's established seaweed farming sector to create higher-value, sustainable alternatives to chemical inputs, aiming to decarbonize food and energy systems [Perplexity Sonar Pro Brief, retrieved 2026]. Public accelerator profiles describe it as a female-founded venture, though a complete founder list is not available in primary sources [SAIS Accelerator, retrieved 2026].
Key operational milestones are limited but point to an early-stage build phase. The company participated in the SAIS Accelerator program in 2025, a common step for startups seeking structure and network access [SAIS Accelerator, retrieved 2026]. A more concrete development plan was reported in late 2024, with an announcement of intentions to build a new seaweed fertilizer factory, signaling a move from research and formulation toward scaled manufacturing [IPP Media / The Guardian (Tanzania), Dec 2024].
The company's current public activity includes an active recruitment effort for a specialized Seaweed Biotechnologist role, with an application deadline of July 2026, indicating ongoing investment in core R&D capabilities [Perplexity Sonar Pro Brief, retrieved 2026].
Data Accuracy: YELLOW -- Key details like founding date and full founding team are not confirmed by primary corporate sources. Operational milestones are cited from accelerator and local news reports.
Product and Technology
MIXED The company's public positioning centers on a vertically integrated model for converting seaweed into a suite of sustainable agricultural and industrial inputs. Coastal Biotech develops organic biostimulants and crop protectants from locally sourced macroalgae, marketed as alternatives to synthetic fertilizers and pesticides for small-scale farmers [Perplexity Sonar Pro Brief]. Its product portfolio extends into three broad categories: biostimulants for plant resilience, functional ingredients for human and animal food and feed, and bio-based materials like biopolymers for industrial applications [Perplexity Sonar Pro Brief]. The firm also offers formulation design and contract manufacturing services to agricultural and biomanufacturing clients, suggesting an asset-light approach to scaling production [Perplexity Sonar Pro Brief].
Technical differentiation appears to hinge on proprietary processing of Zanzibar's native seaweed species. An open job posting for a Seaweed Biotechnologist specializing in tissue culture indicates active R&D into bioactive compounds and marine biopolymers derived from macroalgae (inferred from job postings) [Perplexity Sonar Pro Brief]. The company claims its integrated operations are carbon-negative, a central element of its climate and sustainability branding [Perplexity Sonar Pro Brief]. A reported plan to build a new seaweed fertilizer factory, mentioned in local media, points to intended physical expansion of manufacturing capacity [IPP Media / The Guardian (Tanzania), Dec 2024].
Data Accuracy: YELLOW -- Product claims are consistent across multiple startup profiles, but specific technical specifications, efficacy data, and details of the contract manufacturing service are not publicly detailed.
Market Research
PUBLIC The push for sustainable agriculture is creating a tangible market for biological inputs, moving from niche to mainstream as farmers and regulators seek alternatives to synthetic chemicals.
A specific third-party market sizing for seaweed-derived biostimulants in East Africa is not publicly available. However, the broader global biostimulant market provides a relevant analog. According to a report cited by the research engine, the global biostimulants market was valued at approximately $3.2 billion in 2022 and is projected to grow at a compound annual rate of 12.1% through 2032 [Perplexity Sonar Pro Brief]. This growth is driven by increasing regulatory pressure on chemical fertilizers, rising consumer demand for organic produce, and the need for climate-resilient farming practices.
Key demand drivers for biological solutions like those Coastal Biotech is developing are well-documented. Regulatory bans on certain synthetic pesticides in key markets create a direct replacement opportunity. Simultaneously, the escalating frequency of drought and heat stress in agricultural regions is increasing farmer demand for products that can improve crop resilience, a core claim of seaweed-based biostimulants. The company's focus on local seaweed sourcing in Zanzibar also taps into a broader macro trend of regionalizing supply chains and creating circular bioeconomies, which can attract development-focused grant funding.
Adjacent and substitute markets are significant. The primary substitute remains the established, lower-cost synthetic fertilizer and pesticide industry. Competing within the biologicals segment, adjacent markets include microbial inoculants, amino acid-based products, and humic substances. The company's stated expansion into bio-materials and biopolymers places it at the intersection of agtech and industrial biotechnology, targeting the substitution of petroleum-based plastics and chemicals, a market measured in the hundreds of billions.
| Metric | Value |
|---|---|
| Global Biostimulants Market 2022 | 3.2 $B |
| Projected CAGR 2022-2032 | 12.1 % |
The projected double-digit growth rate for the broader biostimulant category underscores the commercial tailwinds, though Coastal Biotech's specific addressable segment within East Africa remains unquantified in public sources.
Data Accuracy: YELLOW -- Market sizing is drawn from an aggregated third-party report on the global biostimulant category, not the company's specific regional segment. Demand drivers are widely cited across industry literature.
Competitive Landscape
MIXED
Coastal Biotech operates in a nascent but increasingly crowded segment, positioning itself as an integrated, locally-sourced producer of seaweed-derived agricultural inputs and biomaterials against a backdrop of global biostimulant giants and regional agricultural distributors.
The competitive analysis proceeds based on the company's stated market and product focus.
- Global Biostimulant and Agrochemical Incumbents. The most direct substitutes for Coastal Biotech's biostimulants and crop protectants are the synthetic fertilizers and pesticides sold by multinationals like Bayer (Crop Science) and Syngenta. These companies offer established efficacy and distribution networks but face growing regulatory and consumer pressure regarding environmental impact [SAIS Accelerator].
- Specialized Biostimulant Producers. A growing cohort of companies, such as Valagro (now part of Syngenta) and smaller firms like Fyteko, develop and market plant biostimulants, often from various natural sources. Their competitive edge lies in scientific validation, global supply chains, and established relationships with large-scale commercial farms.
- Regional Agricultural Input Distributors. In East Africa, the competitive field is dominated by local and regional distributors who import and sell chemical inputs. These players control farmer relationships and retail channels but typically lack proprietary, climate-resilient product development.
- Adjacent Substitutes in Biomaterials. For its bio-based materials and ingredients, Coastal Biotech competes with other algae or plant-based polymer developers, such as Algix or Checkerspot, which target higher-value industrial and consumer goods markets rather than agricultural inputs.
Coastal Biotech's current defensible edge appears to be its integrated, local model. The company emphasizes sourcing seaweed from Zanzibar's existing aquaculture sector and developing products specifically for regional climate stresses like heat and drought [Perplexity Sonar Pro Brief]. This local integration could offer supply chain resilience and a compelling sustainability narrative for both local farmers and international B2B clients seeking traceable, carbon-negative feedstocks. However, this edge is perishable; it depends on maintaining exclusive or preferential relationships with local seaweed farmers and achieving consistent, scaled production before larger incumbents or new entrants replicate the model with greater capital.
The company is most exposed on two fronts. First, it lacks the distribution reach of established agricultural input suppliers. Penetrating fragmented smallholder farming communities requires a significant investment in last-mile logistics, agronomy support, and trust-building that global players achieve through decades of presence and local agent networks. Second, its technical differentiation in biomaterials is unproven at commercial scale. Competitors in the biopolymer space often have deeper R&D funding and partnerships with major brands, creating a high barrier to entry for a pre-seed startup's licensing or contract manufacturing ambitions [Perplexity Sonar Pro Brief].
In the most plausible 18-month scenario, competition will intensify as climate adaptation drives more investment into sustainable agri-inputs across Africa. The "winner" in Coastal Biotech's immediate niche will be the first company to secure a demonstrable offtake agreement with a regional agribusiness or a development agency's large-scale farmer program, validating both product efficacy and commercial scalability. Conversely, the "loser" will be any venture that remains in pilot or grant-dependent R&D without translating its local sourcing advantage into a tangible, defensible customer contract or a patented, high-value compound that attracts strategic investment.
Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's described product categories and target markets; no direct competitor names are confirmed in public sources.
Opportunity
PUBLIC
If Coastal Biotech can successfully industrialize its model of converting local seaweed into high-value agricultural and industrial inputs, it could establish a first-mover position in a nascent but strategically critical segment of the African bioeconomy.
The headline opportunity is to become the primary integrated supplier of seaweed-derived bioproducts for East African agriculture and industry. The company is not merely selling a fertilizer alternative; it is building a manufacturing platform that could supply a range of biostimulants, crop protectants, and biomaterials from a single, localized feedstock source. This outcome is reachable because the company has already defined its integrated model, which spans R&D, formulation, and contract manufacturing. It is actively recruiting specialized scientific talent, such as a Seaweed Biotechnologist focused on tissue culture and bioactive compounds, indicating a commitment to building proprietary capabilities beyond simple extraction. Furthermore, its stated plan to build a new seaweed fertilizer factory, as reported by local media, points to a tangible step toward scaling production capacity [IPP Media / The Guardian (Tanzania), Dec 2024].
Growth would likely follow one of several concrete paths, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Anchor Contract with a Regional Agribusiness | Coastal Biotech secures a long-term supply agreement with a major fertilizer blender or crop input distributor operating in East Africa, becoming their exclusive supplier of organic biostimulants. | A successful pilot deployment with a cooperative or commercial farm that demonstrates yield improvements and cost parity with chemical inputs. | The company's focus on serving the agricultural and biomanufacturing sectors is explicitly stated. The regional push for sustainable agriculture creates demand for proven local alternatives. |
| Technology Licensing to Global Ingredient Players | The company's proprietary methods for extracting or formulating specific high-value compounds (e.g., biopolymers, feed additives) are licensed to multinational ingredient corporations seeking sustainable supply chains. | Publication of peer-reviewed research or granting of a key process patent that validates the technical novelty of its methods. | Coastal Biotech already lists technology licensing as a service line, and its R&D lead has a background in biopolymers and higher-value compounds [Munich Startup, retrieved 2026]. |
Compounding advantages would stem from a vertically integrated, location-specific model. Success in securing consistent offtake for its core biostimulant products would provide the revenue and operational data to refine cultivation and processing techniques. This improved unit economics and product consistency could then be leveraged to move up the value chain into more lucrative biomaterials, creating a flywheel where commercial success funds deeper R&D, which in turn unlocks higher-margin products. Early evidence of this intent is visible in the company's simultaneous focus on basic agricultural inputs and advanced biopolymers.
Quantifying the size of the win requires looking at comparable transactions and market valuations in adjacent sectors. While direct peers are scarce, the 2021 acquisition of Valagro, a biological stimulants and nutrition company, by Syngenta Group for an undisclosed sum highlighted the strategic value placed on biological input platforms. More broadly, publicly traded companies in the sustainable agriculture and plant nutrition space, such as Novozymes (now part of Novonesis), have historically traded at significant revenue multiples based on their proprietary biological solutions. If Coastal Biotech executes on the "Anchor Contract" scenario and captures a meaningful share of the biological inputs market in its regional focus area, it could build a business with a valuation in the hundreds of millions of dollars (scenario, not a forecast). This potential is anchored in the large and growing total addressable market for replacing synthetic agrochemicals, a shift being driven by regulatory and consumer pressures globally.
Data Accuracy: YELLOW -- Opportunity analysis is based on the company's stated model and services; specific catalysts and comparable valuations are inferred from the broader industry context due to a lack of public deal flow or financial metrics for the subject company.
Sources
PUBLIC
[Perplexity Sonar Pro Brief, retrieved 2026] Coastal Biotech Brief | https://coastalbiotech.co.tz/
[SAIS Accelerator, retrieved 2026] Coastal Biotech - SAIS Accelerator | https://sais-accelerator.com/start-up-profile/coastal-biotech/
[NextCapital, retrieved 2026] Coastal Biotech - by Sheriff Alimi and Aisha Aliu | https://nextcapital.substack.com/p/coastal-biotech
[Munich Startup, retrieved 2026] Coastal Biotech - Munich Startup | https://www.munich-startup.de/en/startups/coastal-biotech/
[IPP Media / The Guardian (Tanzania), Dec 2024] Seaweed fertiliser: Coastal Biotech plans new factory |
Articles about Coastal Biotech
- Coastal Biotech's Seaweed Factory Is the First Step to a Carbon-Negative Farm — The Zanzibar-based startup is betting its integrated model can turn local macroalgae into biostimulants, crop protectants, and bio-materials.